Bristol-Pfizer Anticlotting Drug Gets Key EU Approval

A state-of-the-art antiblood-clotting drug developed by Bristol-Myers Squibb (NYSE: BMY  ) and Pfizer (NYSE: PFE  ) has won a second, crucial approval for sale in the European Union, the companies announced Tuesday in a joint press release.

The European Commission gave the nod to Eliquis, the companies' brand name for apixaban, for use by patients suffering from atrial fibrillation. This condition is the irregular, rapid contraction of fibers in the heart muscle, and is one of the leading causes of improper clotting and thus stroke.

Eliquis, which thins the blood as a means of fighting such clotting, had previously been approved for sale in the EU only for the prevention of deep-vein clotting in patients recovering from hip or knee replacement surgery. The new approval significantly widens the market for the drug. According to the two companies, around 6 million Europeans are afflicted with atrial fibrillation.

Eliquis belongs to a new generation of anticlotting drugs aiming to supplant the existing standard, warfarin. Although the latter is effective and inexpensive, it requires constant blood testing in order to monitor proper dosage.

Eliquis has not yet been approved by the U.S. Food and Drug Administration. After two delays, the regulator has said it will hand down a decision by March 17.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2123124, ~/Articles/ArticleHandler.aspx, 7/26/2014 4:14:57 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement